GlassScriptPhysician profile
Arthur B Chandler
NPI 1871517649
$3,252.25
in general payments reported to CMS, 2019-2025
22 companies · $710 in 2025
The $710 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $220 · 2021: $426 · 2022: $491 · 2023: $352 · 2024: $844 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $618.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $450.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $320.98 | 2020-2025 | Farxiga, Lokelma |
| Lexicon Pharmaceuticals, INC. | $275.42 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.27 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $153.69 | 2019-2025 | |
| Scpharmaceuticals INC. | $151.25 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $147.31 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $142.42 | 2022-2025 | Verquvo, Winrevair |
| Pfizer INC. | $129.70 | 2022-2025 | |
| Novo Nordisk INC | $121.70 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $120.14 | 2022-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $81.10 | 2023-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $80.40 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.03 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $41.57 | 2024-2025 | Nexletol |
| Boston Scientific Corporation | $41.42 | 2022-2023 | Watchman Flx |
| Edwards Lifesciences Corporation | $32.70 | 2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $23.87 | 2022 | |
| Bridgebio Pharma, INC. | $22.97 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $22.02 | 2024 | Arcalyst |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.